April 16th: MATWIN presentation
16 April @ 13 h 30 min - 14 h 30 min UTC+1
Prsentation of MATWIN by Lucia Robert.
MATWIN is a French Accelerator programme strictly dedicated to the support of innovation in oncology. The programme main objective is to select R&D innovative projects (headed by academic teams or start-ups) with high transfer potential and therapeutic / prognosis / diagnosis / theranostic application in oncology and to support them in the development and closing of early-stage partnerships (with industrial partners or investors). Projects of interest : projects with first scientific evidence (preclinical or clinical) demonstrating efficacy of the product (proof of concept in vitro / in vivo, established mechanism of action, SAR, associated biomarker, or clinical datas …) or diagnostic test (selectivity, specificity, impact on the therapeutic choice …). The eligibility criteria is not necessarily based on maturity, but also on originality (target, MoA, etc.).
MATWIN’s Call is backed-up by its ongoing partnership with major international industrial groups involved in oncology looking for innovative projects with a high industrial development potential: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb / Celgene, Exact Sciences, GlaxoSmithKline, Janssen, Nanostring Technologies, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi among others.
When applying to MATWIN, applicants may have access to :
• feedback from 15-20 key international industrial and academic opinion leaders (from the global oncology R&D department of MATWIN’s partners and EU renowed research centers) gathered within the unique in Europe MATWIN International Board
• personalised coaching to help optimising project’s structuration and its industry-oriented R&D development plan
• access to a network of partners (international pharma & diag companies, biotechs, startups, investors, etc.) looking forward for collaborations
• possible access to extra funding from organisations supporting the project